VRTX - Earnings call transcript Q2 2018 | Vertex Pharmaceuticals Incorporated

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Good day ladies and gentlemen, and welcome to the Vertex Pharmaceuticals Second Quarter 2018 Conference Call.

As a reminder, today's program may be recorded. I would now like to introduce your host for today's program, Michael Partridge, Vertex Pharmaceuticals, Inc. Please go ahead.

Michael Partridge

Thank you, and welcome to the Vertex second quarter 2018 conference call. Senior of Partridge, Vertex. Relations Michael is Vice Investor President for This cystic we results medicines develop with financial review for our people Tonight, our to and will continued progress all fibrosis. new Dr. and Ian Leiden, provide remarks evening. this and Jeff Smith, prepared Chairman Operating Officer, Chief will CEO Commercial Dr. Stuart Arbuckle, Chief Officer and Q&A. Kewalramani, Reshma for Medical will Officer, Chief us join We recommend call. webcast the you as that slides you access this listen to for slides our on available download are The website. and This website a is conference recorded, replay our tonight. being available starting be later will on call

of statements call. this forward-looking are statements cystic Dr. over current uncertainties management's materially. the could potential regimen These in to those Vertex's without make the I release triple-combination today's statements turn and subject will programs We will with and limitation, events the Commission. fibrosis, regarding on call other discussed Actual financial These development and performance and filings to and risks Exchange based for Vertex's our future including, now medicines, Securities differ marketed Jeff outcomes detail Leiden. and press ongoing in CF commercialization are Vertex's assumptions. on any the

Jeffrey M. Leiden, M.D., Ph.D.

business, are Good thousands in cystic our the people evening everyone. our of area of to ever important half Vertex the CF to treating around before we more Michael. than make patients progress fibrosis. benefits medicine across first Today, continued of tremendous the delivering clinical Thanks, XXXX, In especially with world. and

review in basis Patient ORKAMBI. for patients patients, The for those access in XXXX, total and first the highly ORKAMBI. U.S. excellent will U.S. physicians wide of SYMDEKO of in launch and half the demand which And this or eligible to feedback is First, across rapid we KALYDECO prior similar of to is discontinued the SYMDEKO on has never XXXX, more who our revenue are been And significant guidance been including the of a a uptake in launches revenue and medicine moment. from SYMDEKO for the the growth. driving range Ian to Treating of positive. previously started patients has raising strong

goal early prevent Second, and FDA we are benefits and progress so at moving CF in this as young ages slow transformative patients ages we achieving the and progression in in ages, for evaluating X help is life may children toward and of study deliver we year disease. from pending X or younger We're in for younger XX by the also where one age to exemplified this years the approvals data of This KALYDECO treat children year. later children this as SYMDEKO to expect expect decisions ORKAMBI summer. to X from our

rapidly regimens proceeding Third, a our contain two that through next-generation triple-combination are Phase X development. corrector

development and for VX-XXX VX-XXX enrollment both expect X XXXX. of regimens to this half Phase on no the programs, our enrollment studies to both second expect We late-stage triple-combination the programs VX-XXX to than you to and first months. look the forward a continued advancing in the from The in have VX-XXX coming fast, over these all programs for I mid application a completion later new of synthesis exceptionally the of of for submit molecules years. drug we progress little Based two in year. complete moved on way updating anticipated

medicine. validation acute of X NaVX.X selective pain clear medicine we discover the Phase diseases. in data for continue the for for treatment and proof-of-concept inflammatory pain. inhibitor, chronic other first develop and and in important our invest both generated program, we These NaVX.X to inhibition representing the VX-XXX, have data pain CF, Beyond serious this to clinical provided In

PK CTXXXX of CTA, this study thalassemia initiate the CTA approval for continue first to research third significant we're for and cell technology. CRISPR/CasX recently clinical year recently sickle and follow-on We on VX-XXX in tolerability UK obtained With and FDA partner, Canada pain progressing early track in And XXXX. based we in obtained inhibitors U.S. inhibitor. from pain the longer work this in first have additional X type application, we the to We to invest Phase Canada. in advancing with of the address our and disease We're UK. CTXXXX the approvals questions Phase is on In there agency's NaVX.X CTXXXX later to into and X both was we the the to this no in neuropathic approval the using study. beta the believe in trial sickle for thalassemia, cell results clinic earlier We In a beta also expect gene-editing disease, and regarding a move findings in VX-XXX, potential the to with Therapeutics, and for our of a year. that beta NaVX.X a pain, or advance IND NaVX.X CTXXXX earlier CRISPR development year. treatment submitted remain development. first treatment thalassemia the we as VX-XXX efforts in for inhibitor to obtained CTA continue

with We research efforts. strides make to our also internal continue significant

this use our create in how analogous both XXXX early-stage CF time ability XXXX or medicines diseases and studies to programs in initial early new long-term greatest devastating that now further We of progress value summer, a or one may the benefit the medicines. with investment advanced the our and serious design Ian. of in significantly margin FSGS, segmental By demonstrate revenues, our submitted with specialty model With X We path drive research a with we aim This FSGS. the markets our other time, future. glomerulosclerosis people preclinical medicines to growth change regimens, tremendous of turn first to the support of antitrypsin for XX% And where I'll serious just biology, remarkable in or and proof-of-concept that further this development. made data may inform have business we're to pipeline, over summary, and shareholders. and new continue and we transformative we patients In transformative of markers choose all to have one rapid enable approvals we for disease. These develop compounds clinical treatment will diseases for these portfolio. understood future create increase late-stage very With successfully it's development provide have in deficiency clinical for of can call discovery CF, enable we to we've operating Phase up was fundamentally defining development advancing regimen. which earnings the business the sustainable announced AAT we the ago strong it to next financially, or triple-combination when for well across both the year. multiple continued AAT alpha-X our FDA to diseases is potential year lines. data focal towards we half where to in strategy, early-stage first In and fit the treating the for to

Ian F. Smith

XXXX. financial U.S. we XXXX good total review in highlighted quarter a everyone. second launch and the CF of compared in for $XXX Jeff, of XXXX of the full the Thanks, represents of Total quarter year results, in quarter $XXX recorded product evening XXXX SYMDEKO revision to million increase of by to our financial the revenues. to upward and the guidance CF I'm second Revenues million our XX% revenues are first. which pleased second the

We see continue medicines of number revenue growth, we our as to treated the globally. significant with increase patients

for is launch programs and the from discontinued launch private insurance which covered and representing SYMDEKO in among lives primary patients product revenues new the $X.XX for more favorable initiate demand for trends all the we are billion billion The remain Five providing from as XX% initial has SYMDEKO, first the SYMDEKO. feedback physicians. Based also particularly are state year. for revenues on of to $X.X the The in from revenues, for prior is revenues from ORKAMBI who expectation and SYMDEKO into patients compared patients coming switching midpoint of we the The months time for second $X to early U.S., in – in revenues. SYMDEKO claims and U.S. receiving the and XXXX. to treatment and quarter to in of compliance initiate are Demand included a today are of for in and coverage this CF XX% U.S., the $XXX rapid plans therapy patients We're been to the persistence million seeing strong, coming $XXX evidenced growth Medicaid the FXXXdel million $XXX patients of quarter and strong SYMDEKO CF of in second ORKAMBI's driver positive nearly also homozygous seeing total range growth our initiating processing billion $X.X quarter to the treatment approximately by our ORKAMBI over billion. in this as revised first months, back growth million launch-to-date represents SYMDEKO. range continued total over and the guidance on for for public

by ongoing reimbursement on future of remain reimbursement the reimbursement focused of to long-term type The of U.S., agreements the not new this medicines agreements. Our does other XXXX. established assume discussions a during and portfolio outside reimbursement example Ireland completion establishing outside medicines. to guidance agreement U.S. access With current similar countries immediate providing we to portfolio and latest of broad We rapid and for arrangements. was access announced June additional with are in access countries framework engaged long-term in and ORKAMBI with and in Sweden provides future regarding agreements

expenses. Now to

R&D $XXX CF globally. increase quarter This second the the the $XXX SG&A investment and compared for triple-combination million of in Our primarily due million with advancement XXXX non-GAAP portfolio of patients of expenses to our to treatment support were second quarter XXXX. regimens was medicines the to and of combined

the with pivotal two income and Our incremental chain triple to net billion at is CF approximately guidance combination non-GAAP launch X$.XX The business combination be of is of the drivers and product for for $X.X in The billion XXXX the Non-GAAP strong. We to an driven of of total compared billion The increase this beginning and non-GAAP ended EPS cash in and revenues. $X.XX financial SYMDEKO. and the regimens net income continue of R&D of execution investment supply to EPS by to of the for combined for quarter of million studies $X.X the year. was equivalents was support $XX key compared investment our $X.X second the $XXX growth profile billion strong non-GAAP marketable quarter SG&A of quarter EPS unchanged. for XXXX. $X.XX regimens, of securities income in an with million cash, to largely second net investment triple expenses

the increase see trends expand eligible we and and as access to earnings treated growth number and increasing our our for patients these medicines. continued margins expanding of we expect with operating and continue significant medicines We to in revenues, to globally

also medicines And to to the in I'll year will continue development forward CF and updating internal for with growth. through create in to as for progresses. -- open look drive We we invest that diseases continue you future We to activities questions. external R&D innovation that, lines as business the other and

Operator

Certainly.

Our first Nadeau Cowen Company. question of & from Phil line the comes from

Your question, please?

Philip Nadeau

Good I'm really impressive. launch. afternoon. get Thanks taking Questions bit the the little for Congratulations on SYMDEKO It's color trends there. a question. curious around on the to more my numbers.

of end bottom seems get be HX? I'm information there. kind of suggest the and that So, that sense what compare penetrated, penetration off, more can bit probably the of opportunity they're hit in SYMDEKO's to of given And it's far I but the largely what by you'd in It your a flat U.S. the to they were too curious little sales given how'd ORKAMBI guess, not like is its of quarters SYMDEKO? U.S. quarter guidance

Stuart A. Arbuckle

Sure. It's Hey, Phil. Stuart.

So try all answer those. I'll and

million U.S., to So, in compared we SYMDEKO. that for $XXX $XXX quarter of million referenced net ORKAMBI Ian the for revenues for the the recorded

as how in. tried his of QX. have KALYDECO or going, we'd SYMDEKO. we've who said And That's have uptake a previously in terms reason to fair and patient In we ORKAMBI the who ORKAMBI ORKAMBI to see were populations decline prepared that why modulator remarks, those strong that's is from ORKAMBI been a actually Jeff those discontinued, demand to we for sequential the from three seen CFTR amount saw and the of different across the you launch transitions see QX that exposed anticipating never either

naïve is launch terms In the launch, populations a for to or not whilst yet, seen discontinue. yet have growth start, is penetrated opportunity year, continue into might either the as or there expect so the strong do patients they're you four months into we're the that were not that to those off of fully patient SYMDEKO because we of further balance expect a for

Philip Nadeau

question. Great. Thanks my taking for

Operator

you. Thank

Karnauskas comes from Our line the Robyn of Citi. next from question

Your question, please?

Robyn Karnauskas

long that little competitors cystic guys. off. development out bit are X, how how antitrypsin the you help business your and capital? question pain earlier playing fibrosis term more about are dropping company think do your the Phase is stage about and allocation, CRISPR some or Hi, you since think more (XX:XX) capital particularly us a grow about might of and now your early business you Could using

Jeffrey M. Leiden, M.D., Ph.D.

maybe Yes, This Robyn. strategic development. take specifically Ian then business more it, I'll part Jeff. is it little to over first and about I'll the turn of long-term talk a to

that. And a and when growth that possible. years triple as in forward. as little to is and mission for is business see bit CF. are do news well today before, a the complete that good we involves track very the as the obviously, level about will, of if from really do best So, patients this we at have and And that we We're quickly we number to look talked journey the going those of on trials we've The regimen one CF we rapidly. to a bringing franchise coming confidence enrolling high

So, and a two focusing that's on top the divide we really comes In of important we're line into parts. lot what I first and that attention Then line significant. point. that's growth, think CF, both after obviously, bottom

you do And And again we where in AAT, than engine the a talking sickle we're good we're give that now earlier pretty think cetera. a like because that unique of that have pipeline, et expect like where news generated sense breakthrough scientific XX multiple going we'll internal confident FSGS. good to the cell, we're I to clinical we people lot patients, XX about early-stage those medicines. is that Our after in some trials diseases many of have them has innovation very a the you more visibility and pain are about patients, believe CF therefore,

in have the a XXXX, programs. we expect to success So, XXXX, more to visibility those lot of

internal and seeing. Obviously, invest quarter, of accumulating you're us the and lot externally gives a we're that opportunity more So, part. of each to also that's as capital lot a more

seeing our are we ramp so, significantly. efforts And BD pretty up

and before, turn can in said to to we we go and revenue? No, to. to I've certainly want don't kinds with innovation. our you And supplement As over other really strategy we our short-term going out review need buy pipeline are He But I'll there. it invest of Ian. maybe

Ian F. Smith

Sure. all our to is inside. And company, strategy, the look company the I'd look first at consistent we of we reviews about say broader as absolutely everything that think as Jeff outside we how

on to disease. in fibrosis. We underlying company. cystic if should areas cystic and first that fibrosis effect have three to focused approaches everything We complementary outside it's is the Obviously, look our at the of see we're cause the

different modalities And so, we and that for cystic fibrosis. do that look includes moves and at everything therapies

active diseases would how opportunistic And on couple and through important be last of progresses look evening, from the us is, cause particular, couple disease we third call you at on of terms us and in medicines products in years because, new may deals inside fit we been have in technologies. We're made today, be beta of our CRISPR the and to really outside consistent very going thalassemia that really collaboration very and early-stage on for cell. those seen that Jeff biology what kind nice overall this do of the capital the more terms to disease to company. in getting that strategies, and We're apply We're Vertex. ever can updated of continue sickle where And we've then, area the modalities. Therapeutics area us And we in of, areas that able we're we've than Vertex more of a complete into our itself underlying is new platforms do you've have Second been. active. that and consistent to to science inside working the

we forward we within efforts to transactions. advancing advising business and look So, close you our that some when

Operator

Thank you.

from comes of question Stanley. line from Harrison next Matthew Morgan the Our

please? question, Your

Jeff Hung

is on you to taking ORKAMBI? for you come questions. Jeff guess, Matthew. patients seeing for Can in back you persistence and compliance Thank the first, for are SYMDEKO, comment to compared Hung market? I This the

Stuart A. Arbuckle

Stuart Yeah, is Jeff. This here.

who previously we are discontinued. yes, have initiated but So, ORKAMBI seeing had been patients on

been with adding that's seeing saw to large tonight is have we are case, a ORKAMBI quarter. number a gave who treated either were you that the therapy a revenue modulator And those naïve this our reinitiated in And billion. been in in patients We growth those are patients second CFTR to underlying patients that on driving who it that of really in have those the revenues who guidance to being the which in CFTR $X growth increase discontinued or modulator; treated have SYMDEKO. is never $X.X new billion that with it's

Jeff Hung

comment then, of to potentially low your existing – the price Great. on pricing or broadening The isolated UK is view Thanks. as rest media And dispute obviously to Europe? if the in the prices. can compared out very you you

Stuart A. Arbuckle

Yeah.

of mean, patients countries it, to Ireland, in I'll in is patients ORKAMBI all goal start as Germany, we've securing successful be large just I'm by result Europe our have medicine. to agreements, reminding pricing ORKAMBI access today. to and of indeed future obviously, that that, thrilled and And a countries Italy, eligible that, the that in of ensure access say all yeah, reimbursement I thousands But others the our been have you to So, Netherlands. and call across a number on

markets patients. to there, There's places number and are are don't so, patients defined large in a have markets of number Australia reimbursement number those there. on There UK. focused like absolutely securing particularly the patients And significant the of by access yet obviously we of we where

we're And focused countries and access, not get all so, we know we're have going as patients don't access people. been have too waiting and where in until those we obviously very long yet we we stop are on for there's those to

Jeff Hung

U.S.? And CRISPR you from is ask what written what comment Canada one And you that the R&D, Great. to between proceed a the regulators the one the Thank on IND do on Thanks. UK about asking? and the differences what about now you. last Can you comment the have FDA comments to maybe in and the any FDA need hold.

Jeffrey M. Leiden, M.D., Ph.D.

in obviously those the We're Yes. questions. discussions their to FDA answer with

to of cancer this first know, approved be be outside to likely human gene-editing you As is trial the going for trial.

think But cautious is appropriately the we while let so, have I questions. their have know. forward, And We we're plan you comment in on being discussions. the a as soon as FDA them of in clear those process conservative. answered and that We're obviously answering don't and we'll

Jeff Hung

Thank you.

Operator

you. Thank

Our Flynn from the comes of next line Terence Goldman question Sachs. from

Your question please.

Gavin Scott

the Hi, potentially thank the mid-XXXX? us quarter. you on you. combo. Congrats triple enrollment or starting This is end the and of Terence. on a Maybe Can Is just getting on readout there upside to Gavin the one give any update? completing before year for before

Jeffrey M. Leiden, M.D., Ph.D.

is Yes. Jeff. This

So, we what really know. in on We're the the is early obviously what VX-XXX today we've told you trials. of enrollment

and a than will application too is those to to we regimen we're the of earlier best complete that. choice allow the end the FDA we're of very And able by it's the enrollment submit think trials that mid-XXXX. But thought good make early specifics that by news So, to going more us the just on both be confident any you give to I to year. of of that

Unknown Speaker

All you. right. Thank

Operator

you. Thank

comes question the Yee next line from Jefferies. Our Michael of from

please. Your question

Andrew Tsai

– would would last to consider the one at would yeah, triples one the for or, both this Andrew disclosed be they question, you time Mike. follow Actually same And staggered or the Hi. Thanks. for they disclosing on the by you be NDA? on submit once data up is

Ian F. Smith

Ian. It's to in to Andrew. we're At too for Hey, figure really this. how just point out disclose – us this time, it's early to going

announced in second the that enrollment just we to expect made, year. complete the in we've comments, Jeff just half As this of previously

to start than saying whether that, next U.S. mid-XXXX. NDA disclose data both when enough on early. mid, though, it more, think an year year about other a it's comfortable together, how and progresses that just to issue or no later studies about visibility. file will expect We we together important talking in give be We it how too close investors. based you guidance an you we we we on and by, are to rolls little it's are you to the And we to we'll it to have But and out do how and the greater these as know talk

Andrew Tsai

ranging follow-up happen the molecule. dose you What the Thanks. needs to else Have to And studies? X? Concert basically on a have just Phase quick Thanks. completed

Reshma Kewalramani

Reshma. This Hi is there.

important medicine the drive once-a-day our of CF molecule getting for As a you Concert, is part XX% an in-license we VX-XXX, we portfolio pill. know, from with is which of patients a with as towards

are as up and all that study discussing design with our We FDA. finish we to the be soon And that starting the wrapping as going we're trials. up,

Andrew Tsai

again. Thanks

Operator

you. Thank

comes line Laura next question of from the Chico Raymond Our from James.

Your please? question,

Timur Ivannikov

Yes. is for actually This Ivannikov Hi. Laura. Timur

And we be question that guess, launch summer XH a if I ahead. for looking thinking like in how opine about seasonal halfway had the is the wondering you've potential for impact SYMDEKO. is It looks seasonality might dynamic And U.S. we any XXXX? should on can in the U.S. you about through first the great headwinds So and have this

Stuart A. Arbuckle

Yeah.

So, this is Stuart.

to is I is it of years and vacations dip seasonal a is disrupted. It not untypical that year, routine, in year. it their focused kind for a that, ours We've a compliance was can people their certainly of again last on as this number call So normal big go if on been yes, see focus now. of

patients with try maintain with applicable be And with and instructions. their and we're so, to physicians' their can, compliance to we everything providers working where directly going doing

to early say be certainly we're that's familiar and that the we've out, one too to play exactly year. right it's we'll for how So, a again But now. this doing closely on going with, it's focused phenomenon obviously, very us

Timur Ivannikov

question on the innovation how think reimbursement. tough bigger a for or to maybe will companies be landscape a it's rewarded And has Or recently? Okay. been reimbursement Do has bigger picture been Thank recently? question you. it the like continue has changed on, changed always you Thanks. situation

Jeffrey M. Leiden, M.D., Ph.D.

Yeah. Jeff. is This

So, the really when experience from the a very, the coverage environment. CF and government And payers. it's U.S. payer our we been different that's In believe of major U.S., rewarded. are years. And the payers on coming difficult the talk and that very see last broad own the those don't all environment. think with It's including separate three over U.S. all countries we and at environment based reimbursement, we three different. Europe, a of like companies, very including that had innovative that breakthrough drugs the is always our the about I a we Europe, to outside In very rapid others drugs And changing and the two very companies. over it's obviously least, years for again, innovation single

secure we're the being end And those what been we've of we're we're we're we things price think patient, to budget that beyond. countries. said, moving the fairly number several the always with, reimbursement along I drugs that a the be kind always and that Stuart those rapidly It's the European is breakthrough transformational a in and in with difficult not France, understand look discussion that as a bit per remain, of think Australia of pleased drugs and upper of able UK are impact. developing we're one pleased the reimbursement both so discussions only but at But of and examples. And the and price primary countries in CF we large far, envelope. at seeing countries innovative the total will our

Timur Ivannikov

you. Thank Okay.

Operator

you. Thank

Leerink. from the Porges next Our line of comes from question Geoffrey

please? question, Your

Geoffrey C. Porges

Thanks for fitting me in.

one. accelerated the SYMDEKO schedule XXXX it assume triple U.S. suggested tell us enrolled be than combination, that you sort the the of you And us review you given on we regardless the contribution you mid you KALYDECO? should Could sales same given that XXXX. you're And a file Thanks. Just the the give early to FDA previous of of no could for Could revenue Second, number? then, when later it, fully your already? fact quick inventory channel the combinations? has

Stuart A. Arbuckle

So, Jeff, is this Stuart.

revenues quarter in sales, in no terms was And KALYDECO net inventory, there recorded channel QX channel the for the of build $XXX numbers. at On all meaningful U.S. were our million.

growth All was of by patients onto saw we medicines. more organic driven going there our growth, the patient

Geoffrey C. Porges

Great.

Jeffrey M. Leiden, M.D., Ph.D.

is this is, And, Jeff. Geoff, this sorry,

Just will about that early today, both VX-XXX given the what enrollment give of we've much we're to based very It's VX-XXX the than to confident the know, you which timeline. now the with you what more enrollment on too just talk very and is we complete. seen beginning we've that trials

the made just make you You of actually I we've completed one not statement, trial VX-XXX We that completed is Geoff, do clarify, said yet. want which to sure enrollment have I enrollment.

midyear. by the the And of complete want programs will an in both enrollment math that So, I file end to do But – to that. year. do regimens, that then, compare the would be NDA accurate both will trials if the the complete us about on we by you do or allow think U.S.

the can't. And deal depend asked data. it's and these. to I about You the speak how don't the I going Obviously, on for with FDA FDA will

is going we're to So, I going But push possible, appropriate our as moving as hard. the have data. very promising think data data, we're as if all as obviously very X to think to the the precautions. taking And Phase interested FDA see I quickly is in

Geoffrey C. Porges

very much. Thanks Great.

Operator

Thank you.

of Capital next comes the Our question from RBC Markets. from Abrahams Brian line

Brian Abrahams

on and quarter. the Thanks congrats questions, for taking Hi. strong my

like your internationally. just they're of sort France. ex-U.S. back And next of you negotiations to get or sort value resolvable? the on with a this what reimbursement to data perhaps combo views is triple this key the and the if of and and data, wondering in I difference UK believe fundamental sort that, additional medicines go do you want guess can with just expectations additional of steps I'm are and Just for countries of curious, disease-modifying past some Thanks. or

Stuart A. Arbuckle

thanks question. for the Brian, Yes.

a counteroffer the So, you in the UK our in offer the our We from in and in the received the obviously, current and we referenced, countries undervalues that two and recently where Australia, community believe many NHS. of significantly both UK, CF medicines. specifically terms that are we future

that XX-plus PBAC, on that of been Jeff UK, continue journey which thousands and few reimbursement to there XX the strike was access with us to we countries to benefit the Advisory successfully would diseases And of need earlier next that we're help pricing Pharmaceutical certainly I importantly, we return discussions we path a ORKAMBI. and for us as of a ORKAMBI And long. in then patients the level those and Benefits the fair we determine remarks. and to accept those to secured We're we're that in Europe formal as we cost the what give believe patients are so, in is receive to give too What effectiveness the because, ORKAMBI, question, number meet and access X to able price that, are effectiveness. CF clinical in I describing Australia, we're of said, And to clinical able prepared an not the Committee, and And is. next say waiting going in enable now try to body from that looking the and for Minister steps, pricing and able the Australia indication Health the And In have yet those in weeks, reimbursement the fair which is agreements meeting. other indeed of where not to offer. answer of to forward who've up terms NHS us other the I there progress his in that – Head will indication in for were be when minutes both both in by as will which the referenced now innovation do, delivers. the reviews reviewed fighting

those to So, the long. medicines price a to UK access the only at fight fairly continue we reflects and can waiting for in that and they we But benefit for are who've for the the going to patients access of bring value too patients. which get been do Australia

Brian Abrahams

much. so Thanks sense. Makes

Stuart A. Arbuckle

questions. two we Operator, more take will

Operator

Certainly.

Geoff from of Meacham Barclays. line Our next question comes from the

Your please. question

Olivia Brayer

Brayer Geoff. the is This for question. for Hi. Olivia on taking Thanks

to these is in one maybe Are a on combinations Thanks. have to yield objective the you any you and And VX-XXX beyond two? other? strategy thought given more better VX-XXX Just as follow-up, results the what question expecting over triples. triple your a population in or as

Jeffrey M. Leiden, M.D., Ph.D.

Jeff. Yes. is This

So, those. let answer each me of

Phase to remember combinations VX-XXX take you our triple that all VX-XXX, of in X the back similar. Just were fact, to data, remarkably four you'll and

doing the In the to X the of But on data similar. expect a really that striking. to VX-XXX consistency similarity and data based studies. be would only That's and about quite quite why we data, we fact, standpoint assumptions Phase That's from make X. an Phase was we're the the have efficacy VX-XXX

said the correctors next additional fairly actually continue your part Beyond I of it's yeah, and next-generation question, remarkable. these two, before develop to we

of We and them, have many improve they over to time. continue

have them we're of XX And close so to Our is know, which them that them clinic, of problem point VX-XXX goal to in at will clinic? can't as we be? into obviously or And better. into all that VX-XXX, to some we left which do populations. quite we get these a because have good much we're this the with take are of We XX do better how they take and everyone the you of with carrier is Which take even levels. sort

to threshold to We're quickly. much better one into we moving come bring them be expect or see trying just clinic. they're how should more you needs so, for forward of the them one on which and put choose to But what pretty before it And in. the

can you entering additional to So, the think clinic. compounds I expect see

Operator

you. Thank

from final from question comes the JPMorgan. Kasimov then of Cory line Our

Carmen Augustine

squeezing Carmen and answered, a of confidence likely have your latest are for some questions continues see seen more. my one your competitors in to but here. franchise? recently give competitive maintaining position? you And we're the coming to months. Thanks on in And positioning what leadership thoughts we've Thanks. Most of What data more been in is us just of Corey. for This some on from your

Jeffrey M. Leiden, M.D., Ph.D.

Yes. for question. the one. Thanks important obviously an It's

As we competitors. comment know, don't on you individual

and part really results think We're I comment on your of about those question, with second You'll we've we much where on are. ask us them confidence. gives recently. of what so where are programs pleased have the seen to we their would some and, we

combinations. think I've in progress in actually, X two Phase XX I two these in remarkably ever for said a XX, half from of been X don't and seen triple – or synthesis really this prepared for Phase accelerated molecules my As I've and remarks, I well journey industry a into years into completion to two It's years. two been

based feel we're competitive based data our and speed moving. position, and the the on at And both about better on which better so, we

to of a an that and the XX should triples What predict therapy held HB we thousand well, best patients of our biology said, the shortly an and at that efficacy. the can better perfectly and confidence us U.S. and for to assay provide results thereafter understanding position up virtually, high disease, with I several triple up also Europe ability NDA the hundred As levels we the run the is file in gives we're XX% human of very better in application be and in years these quantitatively. as of our this go. That's really as times they of we making triples regimens

so, at levels, to know, carrier our levels. when close we're disease. goal carrier the to don't very as you actually getting get you're getting carriers And And of

down possible, very a won't levels believe young simple. triple today as medicine disease road. provides know medicine to to that So, our the we're develop well they goal Get is patients everyone. that a it we Get as fibrosis and as and we them carrier – cystic for

Carmen Augustine

Thanks. Okay.

Operator

Michael the Thank you. the to This today's like I'd program does further for any question-and-answer Partridge hand remarks. of back to conclude program. session

Michael Partridge

you questions. joining if Relations have any to much, you. The happy everybody, be additional very for will you this us Thank be to Thanks. We'd team here Investor talk evening.

Operator

in you, and today's for conference. gentlemen, your participation conclude Thank program. ladies This does the

You day. now Good disconnect. may

Vertex Pharmaceuticals (VRTX) 25 Jul 182018 Q2 Earnings call transcript